Kalios
← Stacks

Stack — Gut · Skin & hair

KLOW Stack — GHK-Cu + BPC-157 + TB-500 + KPV · Tested together in people: none published

Gray market

Checked · 28 sources · 7 corrections on this page · No vendors · No affiliates · No one buys a word of it

GHK-Cu: no FDA ruling on the injectable — not on any list

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Injectable GHK-Cu: not legal to compound Non-injectable GHK-Cu is on FDA’s 503A Category 1 list, and FDA plans a committee review of it before the end of February 2027. The injectable nomination was withdrawn. See every change →

Built on: Anti-Inflammatory Regenerative

The receipt

0 studies gave them to people together

Evidence on the combination
No data

None published

No study that gave them to people together is among the sources Kalios cites. Reports of people already taking both, registered trials, conference talks, patents and makers’ own tests don’t count.

What each does alone

Mechanism overlap · reasoning, not evidence

BPC-157
Peptide — Tissue Repair & Cytoprotection
GHK-Cu
Peptide — Copper Tripeptide, Skin & Connective Tissue
KPV
Peptide — Alpha-MSH C-Terminal Anti-Inflammatory Tripeptide
TB-500
Peptide Fragment — Tissue Repair (Thymosin β4 17–23)

Reasoning, not evidence: what each is described to do says nothing about what they do together.

References

No clinical trial has studied the four-peptide KLOW combination in humans. References below cover the individual components and the mechanistic framework.

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520.
  2. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
  3. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353.
  4. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-1056. PMID: 1522753.
  5. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864.
  6. Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID: 27517151.
  7. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
  8. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
  9. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966.
  10. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481.
  11. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
  12. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID: 1999398.
  13. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145.
  14. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID: 9194528.
  15. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID: 14500546.
  16. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-1680. PMID: 14625258.
  17. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177.
  18. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346.
  19. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. PMID: 12750433.
  20. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. 2001;61(5):613-621. PMID: 11239505.
  21. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805.
  22. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-MSH and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. 2008;29(5):581-602. PMID: 18612139.
  23. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29. PMID: 15001661.
  24. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B. FDA.gov, updated 2025.
  25. WADA. 2026 Prohibited List. Sections S0 and S2. World Anti-Doping Agency.
  26. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
  27. Leffler DA, Kelly CP, Green PH, Fedorak RN, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319.e6. PMID: 25683116.
  28. Hoilat GJ, Altowairqi AK, Ayas MF, Alhaddab NT, et al. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022;46(1):101782. PMID: 34339872.

→ Calculator — vial-to-syringe math

See every change to this page → · Status now →

Checked 13 Oct 2026